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Abstract
Co-morbid depression is prevalent in patients with obstructive sleep apnea. Here we report
that monoamine oxidase A (MAO-A) plays pathogenic roles in the comorbidity. We found
that chronic intermittent hypoxia significantly increased the MAO-A expression in the rat hip-
pocampus and markedly decreased the dendritic length and spine density in the pyramidal
neurons with less pre- and post-synaptic proteins. The MAO-A upregulation resulted in
increased 5-hydroxyindoleacetic acid/serotonin ratio, oxidative stress, leading to NF-κB acti-
vation, inflammation and apoptosis. Also, the expression of cytokine-responsive indolea-
mine 2,3-dioxygenase-1 (IDO-1) was significantly augmented in hypoxia, resulting in
increased kynurenine/tryptophan ratio and lowered serotonin level in the hippocampus.
Moreover, depressive-like behaviors were observed in the hypoxic rat. Administration of
M30, a brain-selective MAO-A inhibitor with iron-chelating properties, prior to hypoxic treat-
ment prevented the aberrant changes in the hippocampus and depressive behavior. In
human SH-SY5Y cells expressing MAO-A but not MAO-B, hypoxia significantly increased
the MAO-A expression, which was blocked by M30 or clorgyline. Collectively, the MAO-A
upregulation induced by chronic intermittent hypoxia plays significant pathogenic role in oxi-
dative stress, inflammation and IDO-1 activation resulting in serotonin depletion and
neurodegeneration.
Introduction
Obstructive sleep apnea (OSA) is a major type of sleep-disordered breathing prevalent in
2–7% of adults globally [1]. Co-morbid depression is common (21–41%) in OSA patients [2–
4]. Recent studies showed that symptoms of depression were alleviated in OSA patients treated
with continuous positive airway pressure [5, 6]. Besides, depressive-like behavior was observed
in experimental animals given the treatment of chronic intermittent hypoxic (CIH) [7, 8].
These studies suggest causality between OSA and depression, but there is a paucity of mecha-
nistic delineation of the pathophysiological link of the comorbidity.
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Brain monoamine oxidase A (MAO-A) plays an important role in maintaining the avail-
ability of monoamine neurotransmitters [9]. Dysregulated MAO-A activities significantly alter
the homeostatic balance of monoamines that underpin pathogenesis of depression. In fact,
overactivation of MAO-A has been reported in the brain of clinically depressed patients and in
the postmortem brain [10, 11]. Also, neurodegeneration induced by elevated MAO-A activities
was associated with depressive behavior in rodents with chronic stress [12].
Although the role of inflammation in depression is highly contested, inflammation was
reportedly observed in the brain of clinically depressed patients [13]. Inflammatory cytokine-
responsive indoleamine-2,3-dioxygenase-1 (IDO-1) activation plays an important pathogenic
role in the development of depressive-like behavior in experimental animals [14, 15]. IDO-1
catalyzes the first, rate-limiting step, in the tryptophan catabolism pathway, generating kynure-
nine and resulting in reduced levels of serotonin. Additionally, it has been demonstrated that a
metabolite of the kynurenine pathway, quinolinic acid, can be neurotoxic. In fact, neurotoxic
metabolites upon IDO-1 activation were reportedly to induce neurodegeneration [16, 17].
Here we examined the hypothesis that MAO-A upregulation induced by chronic intermittent
hypoxia causes inflammation and IDO-1 activation, which significantly contribute to the sero-
tonin deficiency and neurodegeneration.
Brain permeable M30, 5[-N-Methyl-N-propargylaminomethyl]-8- hydroxyquinoline), is a
synthetic compound composed of propargyl moiety and prototype of iron-chelator VK28 [18].
Thus, M30 possesses chemical properties of brain-selective MAO inhibitors and iron-chelating
free radical scavengers [19]. These properties have been shown to be central to the protective
effect of M30 against the pathogenic processes of neurodegenerative disease in animal models
of Alzheimer’s or Parkinson disease [20, 21]. A recent study has also reported an anti-inflam-
matory property of M30 via a down-regulation of the expression of inflammatory cytokines in
a genetic model of Alzheimer’s disease [22]. Yet, there is a lack of evidence on the mechanistic
effect of M30 against the oxidative stress, inflammation and neurodegeneration induced by
chronic intermittent hypoxia. In this study, we hypothesized that M30 could prevent depres-
sive behavior induced by chronic intermittent hypoxia via its antagonistic effects on the
MAO-A activity and oxidative stress, resulting in inflammation, IDO-1 activation, serotonin
deficiency and neurodegeneration in the rat hippocampus.
Materials and methods
Animal grouping and cell culture
Animal care and experimental protocol were approved and conducted according to the Com-
mittee on the Use of Live Animals in Teaching and Research (CULATR #2522–11, 3545–15),
The University of Hong Kong. The Laboratory Animal Unit of the University of Hong Kong is
fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC international). Adult male Sprague-Dawley rats (220-250g)
were put under pathogen-free condition in an air-conditioned room at constant temperature
(23±1˚C) provided with water and standard diet (LabDiet, 5053 (LabDiet; St. Louis, MO,
USA)) ad libitum. All animals were monitored on a daily basis for body health throughout the
study. The animals were divided into four experimental groups (n = 12 each), namely nor-
moxic control (Nx), M30-treated normoxic group (Nx+M30), hypoxia-treated group (IH),
M30-treated hypoxic group (IH+M30).
The SH-SY5Y cells were obtained from ATCC (Manassa, VA, USA). The cells were cul-
tured in DMEM/F-12, supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and
streptomycin (100 μg/mL), which were kept in incubators with 95% air and 5% CO2 at 37˚C.
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Fig 1. Hypoxia induced depressive-like behavior in the rat, which was significantly prevented by the M30
administration. Panels A and B represent the immobility time and percentage of sucrose consumption of the rats in
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Intermittent hypoxic protocol and drug preparation
The normoxic control rats were kept in room air while hypoxic rats were maintained in an
acrylic chamber for normobaric hypoxia in the same room. Levels of oxygen in the chamber
were cycling between 21 to 5 ± 0.5% per minute (i.e. 60 hypoxic episodes per hour) for 8 hours
per day diurnally for 7 consecutive days. The desired oxygen levels were established by a mix-
ture of room air and nitrogen and monitored by an oxygen analyzer (Vacumetrics Inc.,
St. Ventura, CA, USA).
M30, 5[-N-Methyl-N-propargylaminomethyl]-8-hydroxyquinoline) was chemically synthe-
sized and kindly provided by Dr. Moussa Youdim and Dr. Lin Bin. Rats were administered
with a daily intraperitoneal injection of M30 (5mg/kg) 2 hours prior to the hypoxic treatment.
The animals were anesthetized with halothane and then decapitated to harvest the hippocam-
pus for experiments.
Cells were placed in an acrylic chamber in the incubator for intermittent hypoxia (repeated
episodes of hypoxia at 1.5% oxygen for 4 hours followed by 21% oxygen for 4 hours) for 24 to
48 hours. MAO-A inhibitor clorgyline (10μM) or M30 (1μM) was added to the culture
medium 1 hour prior to the hypoxic treatment.
Determination of MAO-A and MAO-B activities
According to manufacturers’ instruction, hippocampi were homogenized in 50mM potassium
phosphate buffer (pH = 7.4) followed by optimal dilution with the use of reaction buffer pro-
vided by Amplex Red Monoamine Oxidase Assay Kit (Invitrogen, CA, USA). Enzyme activi-
ties of MAO-A and MAO-B were determined and normalized to total protein content in each
sample. The results were expressed in the percentage of control.
Western blot
Levels of protein expression of hippocampal tissue (including whole tissue cell lysate, cytosolic
or nuclear fractions) were carried out as previously described [23]. The optical density of the
bands was measured and quantified by Image J (National Institute of Health, MD, USA). Pri-
mary antibodies of SOD-2, GPx-1, NFκB p65 and p50, IκBα, TNFα, IL-1β, IL-6 and COX-2
were purchased from Santa Cruz Biotechnology, CA, USA; Synapsin-1 and Synaptophysin
were purchased from Novus Biologicals, USA; PSD95 and Cleaved Caspase 3 was purchased
from Cell Signaling Technology; Cleaved PARP1 was purchased from Bioworld Technology;
IDO-1 was purchased from antibodies-online (ABIN1714836). The data were expressed as
percentage of the control.
Enzyme-linked immunosorbent assay (ELISA)
Hippocampal serotonin (5-HT) (Enzo Life Sciences), 5-HT metabolite 5-hydroxyindoleacetic
acid (5-HIAA) (Elabscience), tryptophan (TRP) (LDN Labor Diagnostika Nord GmbH & Co.
KG), kynurenine (KYN) (MyBioSource) and quinolinic acid (QUIN) (Cloud Clone Corp.)
were determined by ELISA quantification. The results were expressed as ratio or ng/gram wet
tissue and nM respectively.
normoxic (Nx), hypoxic (IH) groups; M30-treated hypoxic (IH+M30) or normoxic (Nx+M30) groups respectively. Data
are mean ± SEM (n = 12). Statistical comparisons between groups were performed using the One way Anova
followed by Tukey post hoc test to detect differences in all groups. A p < 0.05 was considered to be statistically
significant. Different letters (e.g. a and b) mean a statistical significant change between each other.
https://doi.org/10.1371/journal.pone.0177940.g001
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Fig 2. Hypoxia increased the metabolic turnover of serotonin mediated by the elevated activity of MAO-A
but not MAO-B in the hippocampus. Serotonin (5-HT) level was also lowered in the hypoxic group. These
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Malondialdehyde (MDA) aAssay
Hippocampal MDA levels were examined by Bioxytech LPO-586TM kit (OxisResearch, Port-
land, OR). Briefly, according to manufacturer’s protocol, the reaction products were detected
at 586 nm and the standard curves was constructed with 1,1,3,3-tetraethoxypropan. Protein
amount of each samples were measured by Bio-Rad Protein Assay Kit (Bio-Rad, Hercules,
CA). The results were normalized by protein amount. The data was expressed as μmol/mg and
percentage of the control.
GSH/GSSG ratio
Hippocampi were first homogenized in 5% metaphosphoric acid. Then, the homogenized
lysate was centrifuged at 14,000g for 15min at 4˚C to obtain the supernatant for glutathione
determination (Enzo Life Sciences). Total amount of glutathione (GSH) and oxidized glutathi-
one (GSSG) were determined according to manufacturer’s protocol. For reduced GSH, it was
calculated as below: Reduced GSH = Total Glutathione–Oxidized GSSH.
Golgi staining
Hippocampal CA1 and CA3 pyramidal neurons were visualized with the use of Golgi staining
kit (FD Rapid Golgistain Kit (FD Neurotechnologies, MD). Dendritic spine density, length,
and soma area were analyzed with the use of Neurolucida software (MicroBright-Field, USA).
Soma volume was calculated with the below mathematical equation: 4/3πr3. Neurons chosen
for analysis should be relatively separated in order to avoid the interference with neighboring
impregnated neurons. Five neurons from each 100μm-thick brain section were sampled and
analyzed. For the dendritic length and spine density, three to five dendrites with at least one
branch point were selected for counting. Visible spines along the branch segment were
counted and the spine density was expressed as number/10μm. The dendritic length, area and
volume of soma were expressed as μm, μm2 and μm3 respectively.
Behavioral tests
In forced swimming test (FST), rats were put in a cylinder (60cm height X 25 cm diameter)
containing tap water for a 15-min training session to learn helplessness on the following day
after the hypoxic treatment (Fig 1). The animals were put into the cylinder for 5 minutes on
the next day and were recorded on a video-tape for the post-analysis of the immobility time.
The results were expressed in seconds. The immobility time serves as an indicator of behav-
ioral despair, which is a main phenotype observed in rat models for depression and clinically
depressed patients.
In sucrose preference test (SPT), rats were individually caged and provided the training ses-
sion in which two bottles of 1% (wt/vol) sucrose solution for 24 hours on the following day
after the intermittent hypoxic treatment to prevent the subtle stress when applying the sucrose
consumption assessment. After that, the rats were provided one bottle of water and the other
alterations were significantly attenuated by M30. Levels of protein expression of (A) MAO-A, (B) MAO-B, activity
of (C) MAO-A, (D) MAO-B, (E) 5-HT, (F) 5-HIAA and (G) 5-HIAA/5-HT are summarized. β-actin was the internal
control. Data are presented as Mean ± SEM (n = 8). Statistical comparisons between groups were performed
using the One way Anova followed by Tukey post hoc test to detect differences in all groups. A p < 0.05 was
considered to be statistically significant. Different letters (e.g. a and b) mean a statistical significant change
between each other.
https://doi.org/10.1371/journal.pone.0177940.g002
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Fig 3. Hypoxia induced decreases in dendritic spine density, length, soma size and volume of the apical and basal
branches of CA1 and CA3 pyramidal neurons. Levels of the dendritic spine densities of (A) CA3 basal branch, (B) CA3
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contained 1% (wt/vol) sucrose solution for 24 hours. The positions of bottles were swapped at
the middle of the assessment to avoid the bias towards a particular side. No food and water
deprivation was applied before the test to prevent the interference with the metabolic demands
of the rats. The consumption of water and sucrose solution was recorded by weighing bottles
before and after the test. Results were presented as the percentage of the sucrose solution over
the total weight of liquid consumed and expressed as percentage of the control.
Statistical analysis
Data from each group were expressed as mean ± SEM. Statistical comparisons among groups
were performed using One way ANOVA followed by Tukey’s post-hoc test for multiple com-
parisons with the use of Graphpad Prism software (Graphpad Software Version 5.01, Inc., San
Diego, USA). A p<0.05 is considered as significant difference between groups and indicated
by different letter (e.g. a and b).
Results
Hypoxia-induced depressive behavior in rats
Behavioral despair and hedonic status of the rats were assessed by the immobility time of
forced swimming test (FST) and percentage of sucrose consumption of reward-based sucrose
preference test (SPT) respectively. The immobility time of hypoxic group was doubled when
compared with that of the normoxic control (n = 12, Fig 1). The percentage of sucrose con-
sumption of the hypoxic group was reduced by 35% of the control. These values were not
significantly different between the M30-treated groups and the control, supporting a prophy-
lactic effect of M30 against hypoxia-induced depressive behavior.
Hypoxia elevated the hippocampal MAO-A activity
Levels of the expression and activity of MAO-A in the hypoxic group were significantly ele-
vated by two folds of the control (n = 8, Fig 2), but there were no changes in the expression
and activity of MAO-B. Also, the 5-HIAA/5-HT ratio was markedly increased in the hypoxic
group (n = 8, Fig 2). No significant differences were found between the M30-treated hypoxic
group and the control. Of note, MAO-A and MAO-B activities were lowered by half in the
M30-treated groups. Results suggest that the upregulation of MAO-A induced by hypoxia
resulted in a deregulated serotonin metabolism, which was neutralized by M30.
Neuroarchitectural alterations induced by hypoxia
Golgi staining was performed to evaluate dendritic structural changes of hippocampal pyrami-
dal CA1 and CA3 neurons. We observed dendritic abnormalities of both apical and basal
apical branch, (E) CA1 basal branch, (F) CA1 apical branch; Levels of the dendritic length of (C) CA3 basal branch, (D) CA3
apical branch, (G) CA1 basal branch, (H) CA1 apical branch; Levels of the cell body area (I) CA3 pyramidal neuron, (J) CA1
pyramidal neuron; Levels of the cell body volume (K) CA3 pyramidal neuron, (L) CA1 pyramidal neuron in the hippocampus
of the normoxic (Nx) or hypoxic (IH) groups; M30-treated hypoxic (IH+M30) or normoxic (Nx+M30) groups are summarized.
Dendritic varicosity formations responsible for reduction in dendritic spine density were indicated by the arrows. Panel M
summarized representative photomicrographs of apical and basal dendrites of both CA3 and CA1 pyramidal neurons showing
dendritic spines. Magnification:100X, Scale bar = 10μm. Panel N illustrated Camera Lucida drawing of representative CA3
and CA1 pyramidal neurons. Data are presented as Mean ± SEM (n = 8). Statistical comparisons between groups were
performed using the One way Anova followed by Tukey post hoc test to detect differences in all groups. A p < 0.05 was
considered to be statistically significant. Different letters (e.g. a and b) mean a statistical significant change between each
other.
https://doi.org/10.1371/journal.pone.0177940.g003
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Fig 4. Administration of M30 attenuated oxidative stress induced by hypoxia. Levels of (A) MDA content, (B) GSH/GSSG ratio
and the protein expression of (C) SOD-2 and (D) GPx-1 and in the hippocampus of the normoxic (Nx) or hypoxic (IH) groups;
M30-treated hypoxic (IH+M30) or normoxic (Nx+M30) groups are summarized. β-actin was an internal control. Data are mean ± SEM
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branches of neurons shown by reduced dendritic spine densities and length and also the area
and volume of somata in the hypoxic group (n = 12, Fig 3). Also, a significant increase in the
dendritic varicosity formations was observed in the hypoxic group. Administration of M30
effectively ameliorated neurodegeneration induced by hypoxia and no observable aberrant
alterations were found in the M30-treated groups.
Inhibition of MAO-A by M30 mitigated hypoxia-induced oxidative stress
Hydrogen peroxide is one of the products of deamination by MAO-A, which is a source of
reactive oxygen species (ROS) leading to oxidative stress. The level of MDA, a lipid peroxida-
tion marker, was significantly elevated by two folds in the hypoxic group (n = 8, Fig 4). Also,
there was a significant decrease in the GSH/GSSG ratio (n = 8, Fig 4). In addition, levels of pro-
tein expressions of antioxidant enzymes SOD-2 and GPx-1 were lowered, respectively, by 50%
and 60% in the hypoxic group when compared to the control (n = 8, Fig 4). There were no sig-
nificant differences between the M30-treated groups and the control.
Hypoxia induced redox-sensitive NFκB canonical pathway-dependent
inflammation
The level of IκBα was significantly decreased by 80% in the hypoxic group when compared to
the control. Also, levels of NFκB p65 and p50 in the hypoxic group were significantly reduced
in the cytosolic fraction and were markedly increased in the nuclear fraction (n = 8, Fig 5).
Besides, there were significant increases in the protein expression of inflammatory cytokines
TNFα, IL-1β, IL-6 and COX-2 by about two folds in the hypoxic group when compared to the
control (n = 8, Fig 6). M30 treatment normalized the IκBα degradation, nuclear translocation
of NFκB and cytokine expression to the control level.
The expression and activity of IDO-1 activated by hypoxia
IDO-1 activity were evaluated by the ratio changes of its substrate tryptophan and enzymatic
metabolite kynurenine. The expression level of IDO-1 and the ratio of kynurenine to trypto-
phan were significantly increased, respectively, by two folds and four folds in the hypoxic
group (n = 8, Fig 6). Consistently, the level of downstream IDO-1 metabolite QUIN was also
increased by hypoxia. M30 treatment mitigated the elevated level of IDO-1 expression and
activity, and the increased level of QUIN.
Hypoxia induced losses of synaptic proteins and neuronal apoptosis
There were dramatic decreases in the expression of pre-synaptic proteins synapsin-1 and
synaptophysin, and post-synaptic protein PSD95 in the hypoxic group, respectively, by 55%,
50% and 68% of the control (n = 8, Fig 7). Furthermore, the expression of anti-apoptotic pro-
tein Bcl-2 was much lowered by 55% of the control and the expression of apoptotic markers
cleaved caspase 3 and cleaved PARP-1 was doubled in the hypoxic group (n = 8, Fig 7).
Administration of M30 effectively ameliorated losses of synaptic proteins and neuronal apo-
ptosis induced by hypoxia.
(n = 8). Statistical comparisons between groups were performed using the One way Anova followed by Tukey post hoc test to detect
differences in all groups. A p < 0.05 was considered to be statistically significant. Different letters (e.g. a and b) mean a statistical
significant change between each other.
https://doi.org/10.1371/journal.pone.0177940.g004
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Fig 5. Hypoxia induced the degradation of IκBα in the redox-sensitive NFκB canonical pathway and the nucleus
translocation of NFκB member p65 and p50. Levels of (A) IκBα, nuclear protein expression of (B) p65, (C) p50, cytosolic
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Hypoxia increased MAO-A expression in SH-SY5Y cells
In human SH-SY5Y cells expressing MAO-A but not MAO-B, the level of protein expression
of MAO-A was significantly increased by 50% following the hypoxic treatment (Fig 8). The
level of MAO-A expression was normalized by the pretreatment of the cells with M30 or clor-
gyline. Hypoxia also significantly reduced the GSH to GSSG ratio, which was partially normal-
ized by clorgyline (Fig 8).
Discussion
This is the first report to delineate a pathophysiological role of the anomalous MAO-A activity
upregulated by chronic intermittent hypoxia in oxidative stress and inflammation, which sig-
nificantly activates the IDO-1 activity and contributes to serotonin deficiency and neurode-
generation closely associated with the clinical manifestation of the brain of patients with
depression. This may help to explain high rates of depression in both community (17%) and
clinical (21–41%) populations with obstructive sleep apnea (OSA) [2, 4, 24–26]. Our results
are clinically relevant in its proposed pathophysiological causality between OSA and depres-
sion. Yet, we are aware of the limitation of the rodent model with the hypoxic treatment in an
attempt to link degenerative neuropathies to the arterial oxygen desaturation simulating the
pathophysiological consequences in a severe OSA condition, which is an important parameter
in the clinical assessment. Intriguingly, we demonstrated the prophylactic effect of the syn-
thetic compound M30 against the aberrant changes in the hippocampus and depressive behav-
ior, which is indicative of targeting the MAO-A activity, oxidative stress and inflammation to
retard the neurodegeneration induced by hypoxia. The administrative dose of M30 has been
reportedly safe for the experimental usage and did not cause any noticeable physiological or
histopathological changes in the healthy animals [27].
A major finding of this study is that MAO-A but not the MAO-B activity was up-regulated
in the hippocampus of hypoxic rats, which is in consistent with the increased MAO-A expres-
sion. This could cause an increased catabolic deamination of 5-HT resulting in increases in the
level of the metabolite 5-HIAA and its ratio to 5-HT, leading to a lowered serotonin availability
that were reportedly shown in the brain of clinically depressed patients and animal models of
depression [28, 29]. These findings are also in agreement with studies reporting that MAO-A
inhibitors could significantly improve depressive symptoms in the patient and rodent models
[30–32]. Importantly, our results provide novel evidence to link the upregulation of MAO-A
to neurodegeneration as a pathophysiological consequence of chronic intermittent hypoxia.
We also demonstrated evidence for a proof of concept that the daily M30 administration sig-
nificantly antagonized the MAO-A upregulation and consequently prevented the depressive
behavior induced by hypoxia. Blockade of MAO-A activity could be a therapeutic approach to
preventing the neurodegeneration in patients with severe conditions of OSA that is known to
increase the risk for depression.
Oxidative stress is a significant adverse consequence of chronic intermittent hypoxia due to
an increased production of reactive oxygen species (ROS). In this context, the upregulated
MAO-A activity could result in an increased enzymatic production of hydrogen peroxide as a
protein expression of (D) p65, (E) in the hippocampus of the normoxic (Nx) or hypoxic (IH) groups; M30-treated hypoxic (IH
+M30) or normoxic (Nx+M30) groups are summarized. Lamin B1 and β-actin were an internal control of the nuclear fraction
and cytosolic fraction respectively. Data are mean ± SEM (n = 8). Statistical comparisons between groups were performed
using the One way Anova followed by Tukey post hoc test to detect differences in all groups. A p < 0.05 was considered to
be statistically significant. Different letters (e.g. a and b) mean a statistical significant change between each other.
https://doi.org/10.1371/journal.pone.0177940.g005
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Fig 6. Hypoxia induced inflammation and activated cytokine-responsive IDO-1 in the hippocampus.
Levels of the protein expression (A) TNFα, (B) IL-1β, (C) IL-6, (D) COX-2, (E) IDO-1, (F) the ratio of KYN/TRP
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by-product of the catalytic deamination of monoamines. In effect, elevated levels of ROS
deplete endogenous GSH antioxidant capacity and cause the lipid peroxidation of membrane
forming MDA. Indeed, our results showed an elevated level of oxidative stress in the hippo-
campus of hypoxic rats with significant decreases in the GSH to GSSG ratio and increases in
the MDA level. Also, the protein expression of antioxidant enzymes SOD-2 and GPx-2 was sig-
nificantly lowered. These changes were markedly neutralized by the M30 treatment, strongly
supporting that the chemical properties of M30, namely for the MAO inhibition and scaveng-
ing ROS, were effective to antagonize the pathophysiological consequences induced by chronic
intermittent hypoxia. M30 is also highly permeable to the blood brain barrier and selective to
the brain MAO-A activity [33], which is potentially an advantage to limit the non-specific side
effects of MAO inhibitors.
Inflammation has been proposed as a prominent factor in the induction of depressive
symptoms, which could be mediated by the activation of cytokine-responsive IDO-1. Studies
have also shown that neuroinflammation was closely linked to oxidative stress via redox sensi-
tive NFκB canonical pathway, forming a vicious cycle in the production of ROS and inflamma-
tory cytokines, causing tissue damages [23, 34]. Indeed, we found significant increases in the
degradation of IκBα and the translocation of NFκB p65 and p50 from the cytosol to nucleus.
Consequently, the activation of NFκB canonical pathway results in the elevated expression of
inflammatory cytokines TNFα, IL-1β, IL-6 and COX-2. Intriguingly, the M30 treatment
remarkably mitigated the activation of redox-sensitive NFκB cascade and the expression of
cytokines, which is consistent with an anti-inflammatory property of M30 reported recently
[22].
The augmented IDO-1 activity has been proposed to play a pathogenic role in the catabolic
conversion of tryptophan to kynurenine, causing a decrease in tryptophan availability for the
5-HT biosynthesis leading to serotonin deficiency [35, 36]. Our results showed a significant
increase in the IDO-1 expression and activity in parallel with a significantly lowered 5-HT
level in the hippocampus of hypoxic rats. These were in consistent with findings of previous
reports showing 5-HT depletion as a result of elevated IDO-1 activities could be restored by
the administration of anti-inflammatory agents [37, 38]. In fact, we showed that M30 signifi-
cantly decreased MAO-A activity and oxidative stress, which could lessen the activation of
redox-sensitive NFκB cascade and the expression of cytokines that elevate the cytokine respon-
sive IDO-1 activity in the hippocampus of hypoxic rats.
Neurodegeneration is an important neuropathic feature of depression observed in both
patients and animal models [39, 40], which is closely associated with and attributed to apopto-
sis as a result of oxidative stress and inflammation leading to the activation of intrinsic and
extrinsic cascades [23, 41]. These are illustrated in our results showing significant increases in
the level of apoptotic markers cleaved caspase 3 and cleaved PARP 1, and marked decreases in
the level of anti-apoptotic protein Bcl-2. By targeting MAO-A upregulation, oxidative stress
and inflammation, M30 could abrogated neuronal apoptosis induced by hypoxia, which is in
line with previous reports illustrating anti-apoptotic property of M30 in the animal models of
Parkinson’s diseases and stress-induced depression [20, 42].
Losses of synaptic proteins were observed in the brains of patients and animals with depres-
sion and were proposed to be closely related to the onset of depression [43, 44]. We found that
(IDO-1 activity) and (G) the level of QUIN are summarized. Data are presented as Mean ± SEM (n = 8).
Statistical comparisons between groups were performed using the One way Anova followed by Tukey post hoc
test to detect differences in all groups. A p < 0.05 was considered to be statistically significant. Different letters
(e.g. a and b) mean a statistical significant change between each other.
https://doi.org/10.1371/journal.pone.0177940.g006
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Fig 7. Hypoxia induced neuronal apoptosis and losses of pre-synaptic vesicle proteins and post-synaptic. Levels
of protein expression of (A) Bcl-2, (B) Cleaved Caspase 3, (C) Cleaved PARP-1, (D) Synapsin-1, (E) Synaptophysin and
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there were significant down-regulation of expressions of pre-synaptic vesicular proteins synap-
sin-1 and synaptophysin, and post-synaptic protein PSD95 in the hippocampus of hypoxic
rats, which were remarkably ameliorated by the M30 treatment. This is in agreement with the
observation that the degradation of synaptic proteins was mediated by apoptotic caspase
enzymes [45]. These results give strong support to the contention that M30 confers protective
effects against synaptic degeneration induced by hypoxia.
Golgi staining vividly revealed adverse effects on the neuroarchitecture induced by hyp-
oxia. There were remarkable reductions in the dendritic spine density and dendritic length
on both apical and basal branches of the CA1 and CA3 pyramidal neurons in the hippocam-
pus of hypoxic rats. It has been reported that hypoxia could induce NMDA overactivation
that leads to excitotoxicity and causes ultrastructural damages in the hippocampus [46]. In
fact, NMDA excitotoxicity is a major cause of varicosities formation in the dendritic spines
and decreases the spine density [47, 48]. Particularly, the catabolic degradation of tryptophan
by IDO-1 produces neurotoxins such as quinolinic acid that agonistically effect on the activa-
tion of NMDA receptors and potentially cause the formation of varicosities when IDO-1
activity is augmented under hypoxic conditions. The area and volume of the soma were
markedly decreased in the hippocampus of hypoxic rats, which are in line with the pathogenic
processes of DNA fragmentation and condensation in neuronal apoptosis [49]. These defec-
tive changes in the spines and somata were not found in the rat treated with M30, strongly
supporting a pathogenic role of MAO-A in oxidative stress and inflammation leading to
IDO-1 activation that causes the neurodegeneration. Results are also in consistent with the
observation that MAO-A inhibitors could rescue the abnormal dendritic structure upon
exposure to chronic stress [50].
Finally, the effect of hypoxia on the MAO-A upregulation was confirmed by the findings in
cultured human SH-SY5Y cells, which constitutively express MAO-A but not MAO-B. The
MAO-A expression was significantly upregulated in the hypoxic group, providing evidence to
argue a non-specific effect of hypoxia on the MAO-A upregulation. The MAO-A upregulation
was blocked by M30 or clorgyline, suggesting a crucial role of MAO-A in the pathophysiologi-
cal cascade initiated by chronic intermittent hypoxia, which drives the adverse consequences
towards neurodegeneration. This is summarized in S1 Fig. illustrating the pathophysiological
mechanism underlying the onset of neurodegeneration and depressive behavior induced by
chronic intermittent hypoxia, which also highlights the effect of M30 targeting the MAO-A
that significantly contribute to oxidative stress and inflammation leading to serotonin defi-
ciency and neurodegeneration.
Conclusions
Chronic intermittent hypoxia upregulates the expression and activity of MAO-A resulting in
oxidative stress, inflammation, activation of IDO-1, causing serotonin deficiency and neurode-
generation, which could be potently antagonized by M30 against the upregulation of MAO-A
activity and the production of free radicals. MAO-A is an indicative drug target to prevent the
onset of depressive symptoms in OSA patients.
(F) PSD-95 in the hippocampus of the normoxic (Nx) or hypoxic (IH) groups; M30-treated hypoxic (IH+M30) or normoxic
(Nx+M30) groups are summarized. β-actin was an internal control. Data are presented as Mean ± SEM (n = 8). Statistical
comparisons between groups were performed using the One way Anova followed by Tukey post hoc test to detect
differences in all groups. A p < 0.05 was considered to be statistically significant. Different letters (e.g. a and b) mean a
statistical significant change between each other.
https://doi.org/10.1371/journal.pone.0177940.g007
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Fig 8. The level of protein expression of MAO-A was increased by exposure to intermittent hypoxia (IH) in SH-SY5Y cells, which was antagonized by M30
at 1μM or clorgyline at 10μM (Panel A and B). Hypoxia significantly reduced the GSH/GSSG ratio in SH-SY5Y cells, which was partially attenuated by
Role of MAO-A in hypoxia-induced neurodegeneration
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Supporting information
S1 Fig. A schematic summary of the pathophysiological cascade induced by chronic inter-
mittent hypoxia (CIH) leading to depression.
(PDF)
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